Table 3.

Individuals with treatment-emergent malignancies.

Study drug	Individual	Malignancy	Baseline CD4+ cell count	Study day	SAE	Related
MVC	1	Kaposi sarcoma	138	196	N	N
	2	Basal cell carcinoma	513	139	N	N
	3	Hodgkin's lymphomaa	343	226	Y	Yb
	4	Kaposi sarcoma	339	137	N	N
	5	Castleman's diseasea,c	185	33	Y	N
	6	Hodgkin's lymphoma	402	65	Y	N
	7	Lung adenocarcinoma	259	365	Y	N
	8	Lymphomaa	250	315	Y	N
	9	Kaposi sarcoma	485	237	Y	N
TDF/FTC	10	Kaposi sarcomaa	179	334	Y	N
	11	Testicular cancer	345	59	Y	N
	12	Basal cell carcinoma	338	465	N	N

MVC, maraviroc; SAE, serious adverse event; TDF/FTC, tenofovir/emtricitabine.

^aDiscontinued from study drug due to event.

^bInvestigator causality initially attributed to study drug but later considered to be likely due to immune reconstitution inflammatory syndrome and Epstein–Barr virus infection.

^cInitially reported as Kaposi sarcoma and plasmablastic lymphoma but later grouped under the term Castleman's disease.